{
  "denotations": [
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 162,
        "end": 173
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 222,
        "end": 236
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 256,
        "end": 261
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 265,
        "end": 270
      }
    },
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 86,
        "end": 130
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 133,
        "end": 145
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 56,
        "end": 76
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26698676_2",
  "text": "OBJECTIVE : To evaluate the relationship between use of fertility medication ( i.e. , selective estrogen receptor [ ER ] modulator , gonadotropin , or other ) or infertility treatment ( i.e. , IVF or IUI ) and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation ."
}
